Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer

Table 1

Characteristics of patients without CNS metastases at the time of starting trastuzumab for metastatic breast cancer.

Characteristic		All Patients (𝑁=562)
Age at start of trastuzumab (years), Median (IQR)		75 (71–79)
Months from diagnosis to trastuzumab, Median (IQR)		2 (1–6)
Age category, 𝑛 (%)	66–69	94 (17)
	70–74	181 (32)
	75–79	148 (26)
	≥80	139 (25)
Race/ethnicity, 𝑛 (%)	White	455 (81)
	Black	62 (11)
	Hispanic	23 (4)
	Other	22 (4)
Year trastuzumab therapy started, 𝑛 (%)	2000	19 (3)
	2001	47 (8)
	2002	68 (12)
	2003	89 (16)
	2004	119 (21)
	2005	136 (24)
	2006	84 (15)
Comorbidity score at start of trastuzumab, 𝑛 (%)	0	495 (88)
	1	45 (8)
	≥2	22 (4)
Stage at initial diagnosis, 𝑛 (%)	Recurrent Stage 0–III	336 (60)
	Incident Stage IV	226 (40)
ER/PR Status, 𝑛 (%)	Both ER and PR positive	143 (25)
	Either ER or PR positive	91 (16)
	Both ER and PR negative	251 (45)
	Unknown	77 (14)
Metastases at start of trastuzumab, 𝑛 (%)	Bone	269 (48)
	Liver	172 (31)
	Lung/Chest	184 (33)
	All Other	162 (29)

Note: IQR: interquartile range, ER: estrogen receptor, PR: progesterone receptor.